Correlation Between the Levels of ANGPTL3, ANGPTL4, ANGPTL8 and Postprandial Triglyceride-Rich Lipoprotein (TRL)

References

• Li Z, Zhu G, Chen G, et al. Distribution of lipid levels and prevalence of hyperlipidemia: data from the NHANES 2007–2018. Lipids Health Dis. 2022;21(1):111. doi:10.1186/s12944-022-01721-y
   PubMed Web of Science ®Google Scholar
• Hirano T. Pathophysiology of Diabetic Dyslipidemia. J Atheroscler Thromb. 2018;25(9):771–782. doi:10.5551/jat.RV17023
   PubMed Web of Science ®Google Scholar
• Sciarrillo CM, Koemel NA, Keirns BH, et al. Who would benefit most from postprandial lipid screening? Clin Nutr. 2021;40(7):4762–4771. doi:10.1016/j.clnu.2021.04.022
   PubMed Web of Science ®Google Scholar
• Vergès B. Intestinal lipid absorption and transport in type 2 diabetes. Diabetologia. 2022;65(10):1587–1600. doi:10.1007/s00125-022-05765-8
   PubMed Web of Science ®Google Scholar
• Sylvers-Davie KL, Davies BSJ. Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8. Am J Physiol Endocrinol Metab. 2021;321(4):E493–E508. doi:10.1152/ajpendo.00195.2021
   PubMed Web of Science ®Google Scholar
• Chan DC, Pang J, Romic G, Watts GF. Postprandial hypertriglyceridemia and cardiovascular disease: current and future therapies. Curr Atheroscler Rep. 2013;15(3):309. doi:10.1007/s11883-013-0309-9
   PubMed Web of Science ®Google Scholar
• Bai Y, Lu D, Qu D, et al. The role of ANGPTL gene family members in hepatocellular carcinoma. Dis Markers. 2022;2022:1844352. doi:10.1155/2022/1844352
   PubMed Web of Science ®Google Scholar
• Carbone C, Piro G, Merz V, et al. Angiopoietin-like proteins in angiogenesis, inflammation and cancer. Int J Mol Sci. 2018;19(2):431. doi:10.3390/ijms19020431
   PubMed Web of Science ®Google Scholar
• Chen P-Y, Gao W-Y, Liou J-W, Lin C-Y, M-J W, Yen J-H. Angiopoietin-like protein 3 (ANGPTL3) modulates lipoprotein metabolism and dyslipidemia. Int J Mol Sci. 2021;22:14.
   Web of Science ®Google Scholar
• Luo F, Das A, Khetarpal SA, et al. ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases. Trends Cardiovasc Med. 2023. doi:10.1016/j.tcm.2023.01.008
   Web of Science ®Google Scholar
• Zhao Z, Deng X, Jia J, et al. Angiopoietin-like protein 8 (betatrophin) inhibits hepatic gluconeogenesis through PI3K/Akt signaling pathway in diabetic mice. Metabolism. 2022;126:154921. doi:10.1016/j.metabol.2021.154921
   PubMed Web of Science ®Google Scholar
• Hou X, Guan Y, Tang Y, et al. A correlation study of the relationships between nonalcoholic fatty liver disease and serum triglyceride concentration after an oral fat tolerance test. Lipids Health Dis. 2021;20(1):54. doi:10.1186/s12944-021-01483-z
   PubMed Web of Science ®Google Scholar
• Hu DY. New guidelines and evidence for the prevention and treatment of dyslipidemia and atherosclerotic cardiovascular disease in China. Zhonghua Xin Xue Guan Bing Za Zhi. 2016;44(10):826–827. doi:10.3760/cma.j.issn.0253-3758.2016.10.002
   PubMedGoogle Scholar
• Kolovou GD, Watts GF, Mikhailidis DP, et al. Postprandial hypertriglyceridaemia revisited in the era of non-fasting lipid profile testing: a 2019 expert panel statement, main text. Curr Vasc Pharmacol. 2019;17(5):498–514. doi:10.2174/1570161117666190507110519
   PubMed Web of Science ®Google Scholar
• Qiu M, Glass Z, Chen J, et al. Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of Angptl3. Proc Natl Acad Sci U S A. 2021;118(10). doi:10.1073/pnas.2020401118
   Web of Science ®Google Scholar
• Arca M, D’Erasmo L, Minicocci I. Familial combined hypolipidemia: angiopoietin-like protein-3 deficiency. Curr Opin Lipidol. 2020;31(2):41–48. doi:10.1097/MOL.0000000000000668
   PubMed Web of Science ®Google Scholar
• Akoumianakis I, Zvintzou E, Kypreos K, Filippatos TD. ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets. Curr Atheroscler Rep. 2021;23(5):20. doi:10.1007/s11883-021-00914-7
   PubMed Web of Science ®Google Scholar
• Ling P, Zheng X, Luo S, Ge J, Xu S, Weng J. Targeting angiopoietin-like 3 in atherosclerosis: from bench to bedside. Diabetes Obes Metab. 2021;23(9):2020–2034. doi:10.1111/dom.14450
   PubMed Web of Science ®Google Scholar
• Dewey FE, Gusarova V, Dunbar RL, et al. Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease. N Engl J Med. 2017;377(3):211–221. doi:10.1056/NEJMoa1612790
   PubMed Web of Science ®Google Scholar
• Mehta A, Shapiro MD. Apolipoproteins in vascular biology and atherosclerotic disease. Nat Rev Cardiol. 2022;19(3):168–179. doi:10.1038/s41569-021-00613-5
   PubMed Web of Science ®Google Scholar
• Aryal B, Price NL, Suarez Y, Fernández-Hernando C. ANGPTL4 in Metabolic and Cardiovascular Disease. Trends Mol Med. 2019;25(8):723–734. doi:10.1016/j.molmed.2019.05.010
   PubMed Web of Science ®Google Scholar
• Ploug M. ANGPTL4: a new mode in the regulation of intravascular lipolysis. Curr Opin Lipidol. 2022;33(2):112–119. doi:10.1097/MOL.0000000000000800
   PubMed Web of Science ®Google Scholar
• Cushing EM, Chi X, Sylvers KL, Shetty SK, Potthoff MJ, Davies BSJ. Angiopoietin-like 4 directs uptake of dietary fat away from adipose during fasting. Mol Metab. 2017;6(8):809–818. doi:10.1016/j.molmet.2017.06.007
   PubMed Web of Science ®Google Scholar
• Stitziel NO, Stirrups KE, Masca NGD, et al. Coding Variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease. N Engl J Med. 2016;374(12):1134–1144.
   PubMed Web of Science ®Google Scholar
• Ruscica M, Zimetti F, Adorni MP, Sirtori CR, Lupo MG, Ferri N. Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia. Pharmacol Res. 2020;153:104653. doi:10.1016/j.phrs.2020.104653
   PubMed Web of Science ®Google Scholar
• Zheng X, Liu R, Zhou C, et al. ANGPTL4-mediated promotion of glycolysis facilitates the colonization of Fusobacteriumnucleatum in colorectal cancer. Cancer Res. 2021;81(24):6157–6170. doi:10.1158/0008-5472.CAN-21-2273
   PubMed Web of Science ®Google Scholar
• Zhen EY, Chen YQ, Russell AM, et al. Angiopoietin-like protein 4/8 complex-mediated plasmin generation leads to cleavage of the complex and restoration of LPL activity. Proc Natl Acad Sci U S A. 2023;120(7):e2214081120. doi:10.1073/pnas.2214081120
   PubMedGoogle Scholar
• Oldoni F, Cheng H, Banfi S, Gusarova V, Cohen JC, Hobbs HH. ANGPTL8 has both endocrine and autocrine effects on substrate utilization. JCI Insight. 2020;5(17). doi:10.1172/jci.insight.138777
   PubMed Web of Science ®Google Scholar
• Chen YQ, Pottanat TG, Siegel RW, et al. Angiopoietin-like protein 8 differentially regulates ANGPTL3 and ANGPTL4 during postprandial partitioning of fatty acids. J Lipid Res. 2020;61(8):1203–1220. doi:10.1194/jlr.RA120000781
   PubMed Web of Science ®Google Scholar
• Stefanska A, Bergmann K, Krintus M, Kuligowska-Prusinska M, Murawska K, Sypniewska G. Serum ANGPTL8 and ANGPTL3 as predictors of triglyceride elevation in adult women. Metabolites. 2022;12(6):539. doi:10.3390/metabo12060539
   PubMed Web of Science ®Google Scholar
• Gómez-Ambrosi J, Pascual E, Catalán V, et al. Circulating betatrophin concentrations are decreased in human obesity and type 2 diabetes. J Clin Endocrinol Metab. 2014;99(10):E2004–E2009. doi:10.1210/jc.2014-1568
   PubMed Web of Science ®Google Scholar
• Ebert T, Kralisch S, Hoffmann A, et al. Circulating angiopoietin-like protein 8 is independently associated with fasting plasma glucose and type 2 diabetes mellitus. J Clin Endocrinol Metab. 2014;99(12):E2510–E2517. doi:10.1210/jc.2013-4349
   PubMed Web of Science ®Google Scholar
• Lee Y-H, Lee S-G, Lee CJ, et al. Association between betatrophin/ANGPTL8 and non-alcoholic fatty liver disease: animal and human studies. Sci Rep. 2016;6:24013. doi:10.1038/srep24013
   PubMed Web of Science ®Google Scholar